The blood pressure medication verapamil has in previous studies shown that it may preserve beta cells in patients with Type 1 diabetes. But recently released trial data showed that there was no statistically meaningful difference in C-peptide levels between those who were treated with verapamil versus placebo.

In Type 1 diabetes, the immune system destroys insulin-producing beta cells. Investigators have been studying ways to preserve beta cells in patients. Calcium channel blockers, such as verapamil, inhibit a protein called thioredoxin that causes cell death and have been studied as a way to protect and strengthen beta cells.

However, new data released recently at the 2025 European Association for the Study of Diabetes (EASD) Meeting has found that there is a trend toward better C-p

See Full Page